Factors Associated With CD8+ T-Cell Activation in HIV-1-Infected Patients on Long-term Antiretroviral Therapy

被引:29
|
作者
Zheng, Lu [1 ]
Taiwo, Babafemi [2 ]
Gandhi, Rajesh T. [3 ,4 ,5 ]
Hunt, Peter W. [6 ]
Collier, Ann C. [7 ]
Flexner, Charles [8 ]
Bosch, Ronald J. [1 ]
机构
[1] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA
[2] Northwestern Univ, Div Infect Dis, Chicago, IL 60611 USA
[3] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA
[4] MIT, Ragon Inst MGH, Cambridge, MA 02139 USA
[5] Harvard, Cambridge, MA USA
[6] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA USA
[7] Univ Washington, Dept Med, Div Infect Dis, Seattle, WA USA
[8] Johns Hopkins Univ, Sch Med, Div Clin Pharmacol, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
CD8(+) T-cell activation; viral suppression; age; HCV; CD4(+) T-cell count; HEPATITIS-C VIRUS; LOW-LEVEL VIREMIA; IMMUNE ACTIVATION; HIV-INFECTION; VIRAL SUPPRESSION; RNA LEVELS; RECOVERY; REPLICATION; REGIMENS; DISEASE;
D O I
10.1097/QAI.0000000000000286
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Abnormal levels of CD8(+) T-cell activation persist in HIV-1-infected patients on suppressive antiretroviral therapy (ART) and may be deleterious. Methods: CD8+ T-cell activation (% coexpressing CD38/HLA-DR) was analyzed on blood specimens from 833 HIV-1-infected patients on ART for >= 96 weeks with concurrent plasma HIV RNA (vRNA) <= 200 copies per milliliter. Factors associated with CD8(+) T-cell activation were assessed using generalized estimating equations to incorporate longitudinal measurements (median 4/participant). Results: Participants were 84% men, 47% white, 28% black, and 22% Hispanic, with median pre-ART age 38 years and median ART exposure 144 weeks. CD8(+) T-cell activation was higher at time-points when vRNA was 51-200 versus <= 50 copies per milliliter [mean CD8(+) T-cell activation 23.4% vs. 19.7%; adjusted difference: 1.7% (95% confidence interval: 0.1 to 3.4), P = 0.042]. Restricting to vRNA <= 50 copies per milliliter, multivariable models showed the following factors associated with higher CD8(+) T-cell activation: older age [>= 45 vs. <= 30 years: 3.6% (1.4 to 5.7), P = 0.004], hepatitis C virus antibody positivity [3.6% (0.9 to 6.2), P = 0.032], Hispanic vs. white [7.2% (5.3 to 9.0), P < 0.001], lower concurrent CD4 count [<= 200 vs. >500 cells/mm(3): 2.2% (0.7 to 3.7), P < 0.001], lower concurrent CD4/CD8 ratio [-2.6% (-3.7 to -1.5) per 0.5 unit increase, P < 0.001], and higher pre-ART CD8+ T-cell activation [2.0% (1.6 to 2.5) per 10% higher, P < 0.001]. Conclusions: In participants included in our analysis, residual low-level viremia between 51 and 200 copies per milliliter during ART was shown to be associated with greater CD8(+) T-cell activation than full suppression to <50 copies per milliliter. Older age, hepatitis C virus antibody positivity, race/ethnicity, higher pre-ART CD8(+) T-cell activation, and lower concurrent CD4/CD8 ratio and CD4(+) T-cell count also contribute to greater CD8(+) T-cell activation during suppressive ART.
引用
收藏
页码:153 / 160
页数:8
相关论文
共 50 条
  • [31] T-cell apoptosis in HIV-1-infected individuals receiving highly active antiretroviral therapy
    Böhler, T
    Debatin, KM
    Wintergerst, U
    BLOOD, 2001, 97 (06) : 1898 - 1900
  • [32] Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy
    Kaufmann, GR
    Bloch, M
    Zaunders, JJ
    Smith, D
    Cooper, DA
    AIDS, 2000, 14 (08) : 959 - 969
  • [33] Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults
    Laurent, C
    Gueye, NFN
    Ndour, CT
    Gueye, PM
    Diouf, M
    Diakhaté, N
    Kane, NCT
    Lanièce, I
    Ndir, A
    Vergne, L
    Ndoye, I
    Mboup, S
    Sow, PS
    Delaporte, E
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 38 (01) : 14 - 17
  • [34] The decrease of regulatory T cells correlates with excessive activation and apoptosis of CD8+ T cells in HIV-1-infected typical progressors, but not in long-term non-progressors
    Jiao, Yanmei
    Fu, JunLiang
    Xing, Shaojun
    Fu, Baoyun
    Zhang, Zheng
    Shi, Ming
    Wang, Xicheng
    Zhang, Jiyuan
    Jin, Lei
    Kang, Fubiao
    Wu, Hao
    Wang, Fu-Sheng
    IMMUNOLOGY, 2009, 128 (01) : e366 - e375
  • [35] Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy
    Byakwaga, H.
    Zhou, J.
    Petoumenos, K.
    Law, M. G.
    Boyd, M. A.
    Emery, S.
    Cooper, D. A.
    Mallon, P. W.
    HIV MEDICINE, 2009, 10 (03) : 143 - 151
  • [36] CD8+ T-cell priming is quantitatively but not qualitatively impaired in people with HIV-1 on antiretroviral therapy
    Cabral-Piccin, Mariela P.
    Briceno, Olivia
    Papagno, Laura
    Liouville, Benjamin
    White, Eoghann
    Perdomo-Celis, Federico
    Autaa, Gaelle
    Volant, Stevenn
    Llewellyn-Lacey, Sian
    Fromentin, Remi
    Chomont, Nicolas
    Price, David A.
    Saez-Cirion, Asier
    Lambotte, Olivier
    Katlama, Christine
    Appay, Victor
    AIDS, 2024, 38 (02) : 161 - 166
  • [37] SELECTIVE STIMULATION OF CD4+ VERSUS CD8+ T-CELL SUBSETS IN SYMPTOMATIC AND ASYMPTOMATIC HIV-1-INFECTED INDIVIDUALS
    BETTENS, F
    PICHLER, CE
    HERRMANN, B
    DEWECK, AL
    PICHLER, WJ
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1991, 7 (09) : 773 - 780
  • [38] Factors influencing the normalization of CD4+T-cell count, percentage and CD4+/CD8+T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy
    Torti, C.
    Prosperi, M.
    Motta, D.
    Digiambenedetto, S.
    Maggiolo, F.
    Paraninfo, G.
    Ripamonti, D.
    Cologni, G.
    Fabbiani, M.
    Caputo, S. L.
    Sighinolfi, L.
    Ladisa, N.
    El-Hamad, I.
    Quiros-Roldan, E.
    Frank, I.
    CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 (05) : 449 - 458
  • [39] Correlation between blood telomere length and CD4+ CD8+ T-cell subsets in HIV-1-positive individuals with long-term virological suppression on antiretroviral therapy
    Rodriguez-Centeno, J.
    Esteban-Cantos, A.
    Stella-Ascariz, N.
    Montejano, R.
    de Miguel, R.
    Alejos, B.
    Mena-Garay, B.
    Rodes, B.
    Bernardino, J. I.
    Castro, J. M.
    Mayoral, M.
    Perez-Valero, I.
    Montes, M. L.
    Valencia, E.
    Martin-Carbonero, L.
    Moreno, V.
    Cadinanos, J.
    Gonzalez-Garcia, J.
    Arnalich, F.
    Arribas, J. R.
    HIV MEDICINE, 2019, 20 : 185 - 185
  • [40] Persistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+ T-Cell Activation
    Kuebler, Peter J.
    Mehrotra, Megha L.
    Shaw, Brian I.
    Leadabrand, Kaitlyn S.
    Milush, Jeffrey M.
    York, Vanessa A.
    Defechereux, Patricia
    Grant, Robert M.
    Kallas, Esper G.
    Nixon, Douglas F.
    JOURNAL OF INFECTIOUS DISEASES, 2016, 213 (04): : 569 - 573